G01N 2333/555
Interferons [ifn]
Official title: Interferons [IFN]
G01N2333/555 (Interferons [ifn]) appears on 214 US grants and 488 published applications in this corpus.
Search patents in G01N- Granted patents
- 214
- Published applications
- 488
- Assignees
- 329
- Inventors
- 1,058
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 12 |
| 2004 | 1 | 5 |
| 2005 | 1 | 11 |
| 2006 | 2 | 4 |
| 2007 | 1 | 9 |
| 2008 | 3 | 11 |
| 2009 | 5 | 9 |
| 2010 | 5 | 14 |
| 2011 | 8 | 13 |
| 2012 | 4 | 19 |
| 2013 | 6 | 15 |
| 2014 | 6 | 11 |
| 2015 | 13 | 32 |
| 2016 | 14 | 43 |
| 2017 | 19 | 38 |
| 2018 | 21 | 28 |
| 2019 | 17 | 25 |
| 2020 | 13 | 30 |
| 2021 | 15 | 32 |
| 2022 | 9 | 31 |
| 2023 | 11 | 14 |
| 2024 | 15 | 38 |
| 2025 | 12 | 20 |
| 2026 | 9 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- IFNβ as a pharmacodynamic marker in VSV-IFNβ-NIS oncolytic therapy6 Oct 2026US 12,754,182 B2Mayo Foundation for Medical Education and Research
- Genetically modified mice having a humanized programmed cell death 1 gene14 Jul 2026US 12,677,813 B2Regeneron Pharmaceuticals, Inc.
- Methods of treating an autoimmune disease with a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3)14 Jul 2026US 12,678,485 B2Stemline Therapeautics, Inc.
- Methods, assays and systems for detection of a target analyte21 Apr 2026US 12,607,589 B2Sorrento Therapeutics, Inc.
- Diagnostic blood test for sarcoidosis21 Apr 2026US 12,607,639 B2
- Composition, methods and uses8 Oct 2026US 2026/0306509 A14E Therapeutics, Inc.
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Biomarkers for predicting cancer treatment efficacy10 Sep 2026US 2026/0266828 A1Arcus Biosciences, Inc.
- Humoral Immune Activators for the Treatment of Humoral Immunosuppressed Pathologies, Cancer and Infectious Disease and Humoral Immune Suppressors for the Treatment of Inflammatory Diseases3 Sep 2026US 2026/0256811 A1Navrogen, Inc.
- Compositions and methods for treating cancer with interferon-omega and analogs thereof27 Aug 2026US 2026/0248890 A1Dana-Farber Cancer Institute, Inc.
Most cited
By later US patents
- Methods and apparatus for conducting multiple measurements on a sample125US 7,858,321 B2Meso Scale Technologies, LLC. · 2010
- Method for treating malignant melanoma38US 8,211,424 B2SentoClone International AB · 2012
- Process for the measurement of the potency of glatiramer acetate30US 7,429,374 B2Teva Pharmaceutical Industries Ltd. · 2008
- Process for the measurement of the potency of glatiramer acetate28US 7,923,215 B2Teva Pharmaceutical Industries Ltd. · 2011
- Anti-interferon-α antibodies24US 7,087,726 B2Genentech, Inc. · 2006